Trial Profile
A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms LEADER
- Sponsors Novo Nordisk
- 26 Jun 2023 Results using individual-level participant data from LEADER , SUSTAIN 6 and PIONEER 6 , comparing cardiovascular (CV) protective effect of liraglutide vs semaglutide in subjects with type 2 diabetes, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 20 Jun 2022 Results assessing cardiovascular (CV) efficacy of liraglutide and semaglutide in patients with type 2 diabetes (T2D) and peripheral artery disease from LEADER and SUSTAIN-6 studies, published in the Diabetes, Obesity and Metabolism.
- 14 Dec 2021 Results of pooled analysis from SUSTAIN 6 and LEADER, assessing assessed the effect of once-weekly semaglutide and once daily liraglutide on kidney outcomes in type 2 diabetes, published in the Circulation